JAM
ARQT icon

Jupiter Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Jupiter Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.31M Sell
202,515
-14,740
-7% -$343K 0.03% 359
2026
Q1 		$5.12M Sell
217,255
-109,283
-33% -$2.79M 0.03% 339
2025
Q4 		$9.48M Sell
326,538
-332,793
-50% -$8.52M 0.08% 219
2025
Q3 		$12.4M Buy
659,331
+246,593
+60% +$3.89M 0.11% 203
2025
Q2 		$5.79M Buy
+412,738
New +$5.79M 0.05% 266

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Jupiter Asset Management's ARQT Position: Q2 2026 in Review

Jupiter Asset Management reduced its Arcutis Biotherapeutics (ARQT) stake by 6.8% in Q2 2026, selling an estimated $343K and leaving 202,515 shares worth $5.31M. The position accounts for 0.03% of the portfolio, ranked #359.

Jupiter Asset Management first reported a position in ARQT in Q2 2025 and has held it in 5 quarters since. The position peaked at $12.4M in Q3 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Jupiter Asset Management held 202,515 shares of Arcutis Biotherapeutics worth $5.31M as of Q2 2026.
  • Jupiter Asset Management sold 14,740 Arcutis Biotherapeutics shares in Q2 2026, an estimated $343K.
  • Arcutis Biotherapeutics made up 0.03% of Jupiter Asset Management's portfolio in Q2 2026, its #359 holding.
  • Jupiter Asset Management first reported a position in Arcutis Biotherapeutics in Q2 2025 and has held it in 5 quarters since.
  • Jupiter Asset Management's Arcutis Biotherapeutics position peaked at $12.4M in Q3 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Jupiter Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.